Functional neuroimaging for primary degenerative dementia or mild cognitive impairment
Functional neuroimaging involves the injection into the blood of radiolabeled ligands. The radiolabeled ligands flow in the blood supply to the brain and are then detected by a scanner allowing visualization of the blood supply within the brain.
Status: Decision completed
Why is functional neuroimaging being reviewed?
There are significant questions related to the use of functional neuroimaging for the diagnosis of primary neurodegenerative dementia and mild cognitive impairment, specifically, there are medium concerns regarding safety, efficacy, and cost.
Primary Criteria Ranking
- Safety = Medium
- Efficacy = Medium
- Cost = Medium
Documentation
| Type | Materials |
|---|---|
| Update literature (2024) | |
| Assessment (2014) |
Assessment timeline
- Draft key questions published: May 16, 2014
- Public comment period: May 16 to June 2, 2014
- Final key questions published: June 6, 2014
- Draft report published: October 20, 2014
- Public comment period: October 20 to November 20, 2014
- Final report published: December 15, 2014
- HTCC public meeting: January 16, 2015